Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ACONW
Upturn stock ratingUpturn stock rating

Aclarion Inc (ACONW)

Upturn stock ratingUpturn stock rating
$0.04
Last Close (24-hour delay)
Profit since last BUY-20%
upturn advisory
Consider higher Upturn Star rating
BUY since 9 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: ACONW (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -73.82%
Avg. Invested days 12
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size ETF
Market Capitalization 0 USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 1.21
52 Weeks Range 0.01 - 0.10
Updated Date 06/28/2025
52 Weeks Range 0.01 - 0.10
Updated Date 06/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -6.58

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -7855.96%

Management Effectiveness

Return on Assets (TTM) -35.44%
Return on Equity (TTM) -72.53%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value -
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding -
Shares Floating 582330
Shares Outstanding -
Shares Floating 582330
Percent Insiders -
Percent Institutions -

ai summary icon Upturn AI SWOT

Aclarion Inc

stock logo

Company Overview

overview logo History and Background

Aclarion, Inc. is a spine technology company transforming the diagnosis of lower back pain with its proprietary Magnetic Resonance Spectroscopy (MRS) technology and machine learning algorithms.

business area logo Core Business Areas

  • Nociscan: A noninvasive tool aiding in the diagnosis of chronic low back pain (cLBP) by identifying painful spinal discs using advanced MR spectroscopy.

leadership logo Leadership and Structure

Details on leadership and structure are not widely available publicly, indicative of a smaller, more specialized company. Investors should research this further.

Top Products and Market Share

overview logo Key Offerings

  • Nociscan: Aclarion's core product, Nociscan, aims to improve diagnostic accuracy for cLBP. Market share is currently developing; specific data unavailable. Competitors include traditional diagnostic methods like MR imaging and discography, along with alternative therapies.

Market Dynamics

industry overview logo Industry Overview

The market focuses on diagnosing and treating chronic low back pain, a significant healthcare burden. Innovation is driven by the need for more accurate and non-invasive diagnostic tools.

Positioning

Aclarion positions itself as a leader in advanced diagnostic technology for cLBP, offering a non-invasive alternative to traditional methods. Aclarion is differentiated based on its MRS technology.

Total Addressable Market (TAM)

The total addressable market for cLBP diagnostics and treatment is substantial, estimated at billions of dollars annually. Aclarion is positioned to capture a segment of this market by offering improved diagnostic accuracy.

Upturn SWOT Analysis

Strengths

  • Proprietary MRS technology
  • Potential for improved diagnostic accuracy
  • Non-invasive approach

Weaknesses

  • Limited market presence
  • Need for clinical validation
  • Financial constraints

Opportunities

  • Partnerships with hospitals and clinics
  • Expansion of product applications
  • Increased awareness of cLBP

Threats

  • Competition from established players
  • Regulatory hurdles
  • Reimbursement challenges

Competitors and Market Share

competitor logo Key Competitors

  • SIEN
  • SEDG
  • NUVA
  • Globus Medical (GMED)

Competitive Landscape

Aclarion faces competition from established medical device companies and alternative diagnostic methods. Its MRS technology provides a potential advantage, but market acceptance and reimbursement are key challenges.

Growth Trajectory and Initiatives

Historical Growth: Historical growth requires deeper investor due diligence.

Future Projections: Future growth projections are based on adoption of Nociscan and further product development; analyst estimates unavailable.

Recent Initiatives: Recent initiatives include clinical trials and partnerships to validate and commercialize Nociscan.

Summary

Aclarion is a high-risk, high-reward investment. Its proprietary technology holds promise in improving cLBP diagnosis, but it faces challenges in market adoption, regulatory hurdles, and competition. Financial performance is largely dependent on successful commercialization. Investors should conduct thorough due diligence before investing.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Industry reports

Disclaimers:

Data is based on publicly available information and may not be comprehensive. Investment decisions should be based on independent research and professional advice.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Aclarion Inc

Exchange NASDAQ
Headquaters Broomfield, CO, United States
IPO Launch date 2022-04-22
CEO, President & Director Mr. Brent Ness
Sector Healthcare
Industry Health Information Services
Full time employees 5
Full time employees 5

Aclarion, Inc. operates as a healthcare technology company in the United States. The company uses magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. It develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The company also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and data transfer products, including AMBRA Healthcare, an imaging data transfer platform and NOCIWEB, a custom developed web-interface. In addition, it offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.